Balversa (erdafitinib) — CareFirst (Caremark)
Urothelial carcinoma – Upper genitourinary tract tumors
Initial criteria
- Diagnosis of upper genitourinary tract tumor with FGFR3 genetic alterations
- Used as a single agent
- Used as subsequent therapy for locally advanced or metastatic disease
Reauthorization criteria
- No evidence of unacceptable toxicity or disease progression while on current regimen
Approval duration
12 months